High density of tryptase-positive mast cells in patients with renal cell carcinoma on hemodialysis: correlation with expression of stem cell factor and protease activated receptor-2.
Patients on hemodialysis are at higher risk of renal cell carcinoma probably because of inflammatory and immune system disorders. The aim of this study was to clarify the pathologic roles of 2 phenotypes of mast cells, mast cell tryptase and mast cell chymase, and their correlation with stem cell factor and protease-activated receptor 2 in patients with renal cell carcinoma on hemodialysis. The densities of mast cell tryptase and mast cell chymase and expressions of stem cell factor and protease-activated receptor 2 were examined in 35 patients with hemodialysis-renal cell carcinoma and 39 with non-hemodialysis-renal cell carcinoma who were diagnosed and treated in our hospital. Protein expression was examined by immunohistochemistry. The proliferation index represented the number of Ki-67-positive cells. There were no significant differences in clinicopathologic features between the 2 groups. Mast cell tryptase densities in intratumoral (8.3 per high-power field) and peritumoral areas (8.7 per high-power field) were higher in hemodialysis-renal cell carcinoma than non-hemodialysis-renal cell carcinoma (2.7 and 5.3 per high-power field). No such significant correlations were detected in mast cell chymase. In hemodialysis-renal cell carcinoma, intratumoral mast cell tryptase density correlated with the proliferation index (P = .039 and P = .008, respectively) and also with stem cell factor and protease-activated receptor 2 expression. Our results emphasize the important roles of mast cell tryptase in cancer cell proliferation and recurrence in hemodialysis-renal cell carcinoma. Stem cell factor and protease-activated receptor 2 seem to up-regulate mast cell tryptase functions in these patients. The results suggest collaborative effects of stem cell factor, mast cell tryptase, and protease-activated receptor 2 on the malignant potential of hemodialysis-renal cell carcinoma.
Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8591, Japan.
Shin-ichi
S
Watanabe
Yasuyoshi
Y
Miyata
Tomohiro
T
Matsuo
Yasushi
Y
Mochizuki
Masaharu
M
Nishikido
Tomayoshi
T
Hayashi
Hideki
H
Sakai
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000473:pathology*; D053818:Chymases / Q000032:analysis / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008407:Mast Cells / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D044464:Receptor, PAR-2 / Q000032:analysis / Q000096:biosynthesis*; D006435:Renal Dialysis; D019089:Stem Cell Factor / Q000032:analysis / Q000096:biosynthesis*; D053802:Tryptases / Q000032:analysis / Q000096:biosynthesis*
D044464:Receptor, PAR-2; D019089:Stem Cell Factor; D053818:Chymases; D053802:Tryptases